

Rhodotorula an emergent pathogen

Lilianne Dominguez Cespedes, Yohorlin Marta Cespedes Fonseca, Yadira Virgen Rojas Sanchez

Cespedes L.D, Fonseca C.M.Y, Sanchez R.V.Y. *Rhodotorula* an emergent pathogen. 2022; 6(3):51-55.

ABSTRACT

The indiscriminate use of antibiotics conditioned by the constant appearance of new diseases and the re-emergence of others has caused an increase in antimicrobial resistance and the association of bacterial infections and viral and fungal infections. Although *Candida* and *Aspergillus* species cause the bulk of these infections, a growing proportion of infections are caused by less prevalent pathogens like the *Rhodotorula* species. *Rhodotorula* is an emerging opportunistic fungal pathogen. *Rhodotorula*, a basidiomycetous yeast, is found in nature; and has been isolated from several environmental sources as well as dairy products. They can also as commensal yeast on the skin, nails, and mucous membranes of humans. It is important to mention that mening-

-itis, fungemia, ventriculitis, endocarditis, peritonitis, endocarditis, endophthalmitis, keratitis, lymphadenitis, oral ulcer and infections of devices, such as catheters and contact lenses have all been related to *Rhodotorula*. The most effective antifungal agents against *R. mucilaginosa* are amphotericin B and flucytosine. Fluconazole resistance has been observed in all strains of *Rhodotorula*. In immunocompromised patients, early identification and chemotherapy are critical for preventing disease spread. Prevention methods aim to reduce identified risk factors. It is necessary to implement control and prevention measures to reduce morbidity and mortality rates due to *Rhodotorula* species. Its resistance to azoles leaves us with few therapeutic options to deal with it.

Key words: *Rhodotorula*, Fungemia, immunocompromised patients

INTRODUCTION

It is a fact proven by science that microorganisms have been the first to populate the earth and will certainly persist in it long after the disappearance of humans. Man has always relied on nature to make his scientific discoveries and has obtained from her the necessary resources for his evolution. The deterioration of the environment, a cumulative effect of centuries due to human activity, has caused an imbalance in the relationships established by these microorganisms with man. The indiscriminate use of antibiotics conditioned by the constant appearance of new diseases and the re-emergence of others has caused an increase in antimicrobial resistance and the association of bacterial infections with viral and fungal infections. In the last few decades, fungal infections linked to healthcare assistance have become a major medical concern. Although *Candida* and *Aspergillus* species cause the bulk of these infections, a growing proportion of infections are caused by less prevalent pathogens like the *Rhodotorula* species [1]. Some authors have referred to these fungi as emerging pathogens. Many of them were thought to be laboratory contaminants and/or of poor virulence. *Rhodotoruliosis* is a sporadic, non-contagious, opportunistic mycotic disease. *Rhodotorula*, a basidiomycetous yeast, is found in nature; and has been isolated from several environmental sources as well as dairy products. It was once thought to be non-pathogenic. It has emerged as an opportunistic etiological agent in the last two decades, particularly in immunocompromised hosts.

They can also be present in the skin, nails, and mucous membranes as commensal yeasts. It is important to mention meningitis, fungemia, ventriculitis, endocarditis, peritonitis, endocarditis, endophthalmitis, keratitis, lymphadenitis, oral ulcer and infections of devices, such as catheters and contact lenses have all been related to *Rhodotorula* [2-5]. It is also been found as a saprophyte on the skin, vaginal, and respiratory samples, as well as a colonizing organism on hemodialysis machines and bronchoscopes. [3,4]. The objective of this work is to contribute to the knowledge of *rhodotoruliosis* as an emerging infectious disease.

Development Etiology

Rhodotorula is a basidiomycetous yeast belonging to the phylum Basidiomycota and the family Sporidiobolaceae. The genus *Rhodotorula* has 34 species of which *Rhodotorula glutinis*, *R. mucilaginosa*, and *R. minuta* are the most frequent. *Rhodotorula* species are nutritionally non-fastidious, grow well on a variety of media, and have a quick growth rate. The morphology of the colony has been described as soft, smooth, moist, and occasionally mucoid. Pseudohyphae are rare, and they appear as round or oval budding cells under microscopy. Occasionally, a faint capsule forms. Urease is produced by *Rhodotorula* species, although they do not ferment carbohydrates. Due to the presence of carotenoid pigments, most *Rhodotorula* species generate pink to coral colonies on Sabouraud dextrose agar, although they can also be orange to red on Sabouraud dextrose agar [6].

Microbiology Department, Laboratory of Microbiology, "Lucia Iniguez Landin" Surgical Clinical Hospital, Holguin, Cuba.

Correspondence: Dr. Lilianne Dominguez Cespedes, Microbiology Department, Laboratory of Microbiology, "Lucia Iniguez Landin" Surgical Clinical Hospital, Holguin, Cuba. Email: lilianned40@gmail.com

Received: 4 June 2022, Manuscript No. Puljcm-22-5023; Editor assigned: 6 June 2022, PreQC No. Puljcm-22-5023 (PQ); Reviewed: 20 June 2022, QC No. Puljcm-22-5023 (Q); Revised: 22 June 2022, Manuscript No. Puljcm-22-5023(R); Published: 30 June 2022, DOI: 10.37532/51-55.



This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact reprints@pulsus.com

Epidemiology

Rhodotorulosis is reported in several countries of the world. The disease often occurs in sporadic form however, outbreaks have also been recorded. *Rhodotorula* species are implicated as a cause of fungaemia, endocarditis, meningitis, peritonitis, keratitis, oral ulcers, and central venous catheter infection [7]. The species can be isolated from a range of sources in nature, including air, soil, salt water, plants, dairy products, and the home environment (e.g., shower curtains, bathtub grout) [8]. It is also possible that this opportunistic fungus can contaminate laboratory specimens [9]. A systematic review of *Rhodotorula* infections from the literature showed from the 128 cases, 79% were fungemia (103 cases), 7% eye infections (nine cases) and 5% (six cases) peritonitis associated with continuous ambulatory peritoneal dialysis. 87% of *Rhodotorula* infections are associated with underlying immunosuppression or cancer. The most common isolated risk factor associated with *Rhodotorula* infection was the use of a central venous catheter, which was found in 83.4% of *Rhodotorula* fungemia (86 cases). *Rhodotorula mucilaginosa* was the most common species of fungemia (74% of cases), followed by *Rhodotorula glutinis* with 7.7% [9]. In a study conducted in a Colombian hospital from 2008 to 2011, 150 isolates of *Rhodotorula* spp. in superficial mycoses were mostly obtained from the nails of patients [10]. Manzano et al. showed in their investigation of onychomycosis-causing yeasts isolated, that one case was related to *Rhodotorula glutinis* [11]. *R. glutinis* is part of the saprophytic flora of the skin and mucous membranes of man and is found widespread in humid environments: shower curtains, pipes, toothbrushes, floors, etc., and in medical supplies (catheters, IV solutions, dialysis). In hospitalized patients, *Rhodotorula* spp are found colonizing the digestive and genital mucosa with a frequency of 10.3%, this being significantly higher than in the control population [12]. Specifically, analyzing the percentage of yeasts by genus and species isolated in different body areas of the human being, *Rhodotorula* spp supposes: that in the skin of out-of-hospital individuals 17% (143) of them in the oral cavity of hospitalized patients 4.9% (144) of the same, in the anorectal area of hospitalized patients the 88% [12]. *Rhodotorula mucilaginosa* is prominent basidiomycetous yeast that is found in a variety of natural habitats, including living or decomposing plant constituents, soil, and diverse aquatic environments, including fresh waters, estuaries, and coastal waters, as well as Open Ocean and deep-sea environments. It can also be found in harsh conditions, such as hyper acidic waters and uranium environs. *Rhodotorula mucilaginosa* has been found in peanuts, Apple cider, cherries, fresh fruits, fruit juices, cheeses, sausages, edible molluscs, and crustaceans. Although eating yeast-contaminated food may not cause opportunistic infection directly, there is growing worried that food may be an underappreciated source of environmental pathogens. Recently, was reported an outbreak of *Rhodotorula mucilaginosa* in the neonatal intensive care unit. *Rhodotorula glutinis* complex has also been isolated from a range of substrates and is found all over the world. Air, fresh water, seawater, terrestrial settings, food and beverages, animals, and humans are all known sources of this saprobic fungus. *Rhodotorula minuta* has been recovered less frequently in natural environments than in *R. Rubra* and *R. glutinis* complex [2]. A case of meningitis caused by *Rhodotorula rubra* in an HIV-infected patient has been reported in Russia, in a study carried out in Colombia, its association was observed in 10% with cases of cancer patients with neutropenia [13,14]. This species was found in the air, in seawater (including the deep sea), and in freshwater. Infection due to *Rhodotorula* can occur through inhalation and also by accidental inoculation of the fungus through abraded skin. Natural infection due to *Rhodotorula* species has been described in humans. The source of infection is exogenous and the infection may be acquired through the respiratory tract. However, the fungus can also enter the body of the host via wound, abrasion or injury on the skin [1].

Pathogenesis

The pathophysiology of *Rhodotorula* infection has not been investigated. As previously stated, there is nearly always underlying immunosuppression and/or the presence of a foreign body. Invasive infections may occur as a result of environmental contamination of an inserted prosthetic device, but it appears more likely that the organism is an opportunist that colonizes and infects at-risk patients by taking advantage of immune compromising conditions, and indwelling devices, and exposure to broad-spectrum antibiotics [2].

Clinical manifestations

Because *Rhodotorula* is such a common and saprophytic fungus, its isolation from non-sterile human sites, particularly mucosal membranes, has been a source of debate in the medical community. *Rhodotorula* species have been linked to a variety of diseases, including fungaemia. The first report of fungemia caused by *Rhodotorula* was published in 1960. Increased use of more aggressive treatment modalities, such as intensive care unit admissions, central venous catheter use, short- and long-term parenteral nutrition, broad-spectrum antibiotics, organ transplants, and chemotherapy, was related to an increase in *Rhodotorula* fungemia linked to catheters. Endocarditis, meningitis, ventriculitis, keratitis, endophthalmitis, and peritonitis are some of the other clinical symptoms other than fungaemia. There is also a case of lymphadenitis attributed due to *Rhodotorula mucilaginosa* in a man with a well-controlled HIV infection and a case of pelvic infection with bilateral hydrosalpinx was caused by *Rhodotorula glutinis* [2]. Two cases of fungemia produced by this yeast were reported in Cuba: one in the province of Holguin, the sample from a blood culture of a neonatology patient with associated risk factors, and the other in the province of Cienfuegos, a two-month-old infant of age with a history of preterm delivery and infections of viral aetiology [15,16]. Also in Japan, a case of asymptomatic fungemia due to *Rhodotorula* spp [17].

Identification

Isolation of *Rhodotorula* species from non-sterile sites such as skin, sputum, or stool is more likely to be due to colonization. The isolation of *Rhodotorula* species from sterile site samples, such as blood, peritoneal fluid or cerebrospinal fluid, is generally suggestive of infection, especially in patients without indicative symptoms of infection [18]. On Sabouraud dextrose agar with chloramphenicol, the fungus can be easily isolated from clinical samples. The microscopic morphology of *Rhodotorula* isolates is studied by using PHOL or the Narayan stain, which includes 6 mL dimethyl sulfoxide, 4.0 mL glycerin, and 0.5 mL 3% methylene blue solution. As Pal sunflower seed medium, APRM agar, PHOL stain and Narayan stain are cheaper than other media and stains, it is, therefore, advised that Microbiology and Public Health laboratories should routinely employ these media and stains for the study of fungi including *Rhodotorula*. *Rhodotorula* species found in sterile environments, such as blood, peritoneal fluid, or CSF are frequently symptomatic. Since yeast cells may usually be observed by microscopic examination, morphological and biochemical confirmation of the diagnosis should be sought. They differ from *Cryptococcus* species in that they cannot assimilate inositol, and they differ from *Candida* species in that they produce coloured colonies and lack pseudohyphae.

Colony colouration, confirming biochemical tests (e.g., lack of carbohydrate fermentation, urease production), and the absence of ballistospore generation should all lead to a particular mycological identification of *Rhodotorula*. Identification by biochemical and enzymatic criteria carbohydrate assimilation: The patterns of assimilation of sugars (glucose, lactose, sucrose, maltose, galactose and raffinose) allow the identification of the different species of *Candida* spp, *Rhodotorula rubra*, *Trichosporon* spp. and *Geotrichum* spp. Interpretation: Positive: colour change of the culture medium towards yellow. Biochemical characteristics of *Rhodotorula rubra*: positive glucose, raffinose, maltose and sucrose.

Identification by nutrient assimilation

There are different semi-automated identification systems based on panels or galleries that contain nutrients, such as Auxacolor, Uni Yeast-Tek, API 20 C AUX, Galeria ID 32C, and Vitek System. Among the automatic systems, we have Vitek 2 System, Biolog YT MicroPlate, and Rapid Yeast Identification Panel MicroScan. There are also rapid yeast identification systems using biochemical and enzymatic tests, such as Rapid Yeast Plus System, and Fungiscreen 4H [19].

Susceptibility of patrons and treatment

Rhodotorula species are susceptible to amphotericin B and flucytosine in vitro, resistant to fluconazole and caspofungin, and have varying susceptibility to voriconazole. Amphotericin B is the first choice drug for *Rhodotorula* infections [12]. There are published studies on the in vitro susceptibility of *Rhodotorula* spp. to systemic antifungals. Isolates are usually sensitive to amphotericin B and 5-fluorocytosine but resistant to fluconazole (MIC₉₀ 256 mg/l). Itraconazole is moderately active (MIC₉₀ of 1 mg/l), with the MIC of voriconazole being four times higher than that of itraconazole. In a study carried out, 35 isolates of *R. glutinis* and 61 of *R. mucilaginosa* were collected, and more than 50% were resistant to the azoles studied, especially *R. mucilaginosa* [20]. In another investigation carried out in Spain on the absence or severe reduction in the amount of ergosterol in the fungal membrane and its replacement with other sterols as potential antifungal resistance mechanisms in fungi, the presence of ergosterol was demonstrated in 3 isolates of *Rhodotorula mucilaginosa* and this was sensitive to Fluconazole, Itraconazole, Voriconazole, and Amphotericin B [21]. The therapy of *Rhodotorula* fungemia in humans is still debatable. Recovery requires the resolution of coexisting neutropenia. The removal of the central venous catheter is usually sufficient, and systemic antifungal treatment is rarely necessary. *Rhodotorula* is a low-virulence fungus with a low mortality rate. As a result, most *Rhodotorula* fungemia patients in the literature survived with or without antifungal treatment. Amphotericin B or one of its lipid formulations appears to be the medication of choice based on available in vitro susceptibility data. The most effective antifungal agents against *R. mucilaginosa* are amphotericin B and flucytosine. Fluconazole resistance has been observed in all strains of *Rhodotorula*. Cross-resistance to other azole medications is not common, however, itraconazole, voriconazole, and posaconazole resistance are found in more than 60% of the strains. This yeast species is also resistant to echinocandins. A lot of studies have been discussed about the importance of the genus *Rhodotorula* in the field of biotechnology and its vital applications in the future of the industry, recent studies confirmed the ability of genus *Rhodotorula* such as *Rhodotorula minuta* and *Rhodotorula glutinis* to synthesise metal nanoparticles. One of the most vital applications of metal nanoparticles, especially silver nanoparticles, in the field of medicine is using these nanoparticles as antimicrobial agents. One study from Egypt obtains a *Rhodotorula* strain a promising new biological source for the synthesis of silver nanoparticles having potent antimicrobial activity against a wide range of pathogenic bacteria and fungi [22].

Control and prevention

Minimizing risk factors is an important part of preventing *Rhodotorula* species infections. There is no indication of *Rhodotorula* species is transmitted from person to person. However, *Rhodotorula* spp. can infect healthcare professionals' hands. Standard infection control precautions, such as hand washing and thorough skin cleansing and preparation before invasive treatments, should be emphasized in the absence of particular evidence. As the fungus can enter through the abraded skin, it is, therefore, advised to avoid traumatic injury to the skin. Further, proper medical attention should be given to skin injury. In immune-compromised patients, early identification and chemotherapy are critical for preventing disease spread. Prevention methods aim to reduce identified risk factors. Thus, in the face of colonization in high-risk patients, it is advisable to establish antifungal prophylaxis. Prophylaxis is not without risk since, in turn, it can select strains resistant to azoles. Furthermore, performing antifungal susceptibility testing helps to understand the contribution of antifungal resistance to therapeutic failure. The administration of cytokines and growth factors can palliate the intensity of neutropenia and shorten its duration, although there is no proven evidence that the incidence of fungal infections decreases with the use of these drugs. On the other hand, hygiene measures for both the patient and his room and bathroom may contribute to preventing horizontal transmission. It is also important to have easy access to handwashing by health personnel. In addition, it is recommended that high-risk patients (bone marrow recipients, haematological patients, etc.) be admitted to rooms with the highest levels of environmental safety (positive air pressure, food sterility control, etc.) [23].

CONCLUSIONS

Rhodotorula is an emerging opportunistic fungal pathogen. Fungemia caused by this microorganism has increased due to the use of invasive procedures in accordance with technological development in the world. It is frequently isolated in immunocompromised patients and its transmission can be through health personnel. It is necessary to implement control and prevention measures to reduce morbidity and mortality rates due to *Rhodotorula* species. Its resistance to azoles limits the use of therapeutic options. Therefore it is necessary to focus on the implementation of control and preventive measures to reduce morbidity and mortality rates due to *Rhodotorula* species.

REFERENCES

1. Ramos A, Cabero M, Orden B, et al. Fungemia por *Rhodotorula mucilaginosa* Presentación de dos casos. Carta al director. Rev Esp Quimioter 2012;25(1):76-8
2. Mahendra Pal, Sejra S, Tesfaye S et al. *Rhodotoruliosis*: An Emerging Opportunistic Mycosis of Humans and Animals. J Mycol Mycological Sci. 2021;4(2):38-44.
3. Chaparro M, Estupiñán M, Camacho G, et al. Infección por *Rhodotorula mucilaginosa* en trasplante alogénico de progenitores hematopoyéticos, reporte de un caso. Revista colombiana de hematología y oncología. julio 2018;5(1):55-7.
4. Cure Ruiz, Zorrilla AF. Aislamiento de *Rhodotorula* sp. en un paciente críticamente enfermo. Descripción de un caso y revisión de la literatura. Infectio vol.2001;5(3):179-82.
5. Verdugo FJ, Briones E, Porte L, et al. Fungal peritonitis due to *Rhodotorula mucilaginosa* in a patient with automated peritoneal dialysis. Literature review. Rev Chilena Infectol. 2016;33(2):222-5.

6. Jimbo FA. Universidad central del Ecuador. Aplicación de pruebas bioquímicas microbiológicas a hongos levaduriformes, como apoyo en el diagnóstico de micosis en pacientes del hospital Carlos Andrade Marín durante el período febrero – julio del año 2017. Quito. 2018.
7. Reyes-Martínez I, Pérez-Morales L, Morffi-García M, et al. Aislamiento de *Rhodotorula*. Presentación de un caso en paciente con leucemia mieloide aguda. *Medisur [revista en Internet]*. 2013;11(5):542-5.
8. Herrera K, Cobar O, Barrios R et al. Evaluation of air pollution by microscopic fungi in two biological collections and two museums of Guatemala. *Revista Científica*, 2015;25(2):43-58.
9. Tuon FF, Costa SF. *Rhodotorula* infection. A systematic review of 128 cases from literature. *Rev Iberoam Micol*. 2008;25(3):135-40.
10. Mejía-Arango MA, Santa-Vélez C, Cadavid-Sierra M, et al. Estudio etiológico y epidemiológico de las micosis cutáneas en un laboratorio de referencia-Antioquia-Colombia. *CES Medicina*. 2013;27(1):7-19.
11. Manzano-Gayosso P, Méndez-Tovar LJ, Arenas R, et al. Onychomycosis-causing yeasts in four Mexican dermatology centers and their antifungal susceptibility to azolic compounds. *Revista iberoamericana de micología*. 2010;28(1):32-5.
12. Cuétara García MS. Micosis y colonización por levaduras en la infección VIH: estudio prospectivo.
13. Gyaurgieva OH, Bogomolova TS, Gorshkova GI. Meningitis caused by *Rhodotorula rubra* in an HIV-infected patient. *J med vet mycol*. 1996;34(5):357-9.
14. Cuervo-Maldonado SI, Bermúdez CD, Enciso L, et al. Guía de práctica clínica para el diagnóstico y el tratamiento de las infecciones bacterianas y micóticas en pacientes oncológicos mayores de 15 años con neutropenia febril posquimioterapia de alto riesgo. *Revista Colombiana de Cancerología*. 2014;18(4):186-96.
15. Fonseca YM, Céspedes LD, Pérez YL. Caracterización clínico-micológica de candidiasis sistémica en niños. Hospital Pediátrico Provincial. Holguín. *Hechos Microbiológicos*. 2021;12(2):24-34.
16. Pintado EP, García LM, Pintado EP. Fungemia caused by *Rhodotorula* in a critical infant. *Revista Cubana de Pediatría*. 2019;91(1):1-8.
17. Sakoda Y, Matsumoto T, Kudo A, et al. Asymptomatic Fungemia Due to *Rhodotorula* spp. Caused by a Subcutaneously Implanted Central Venous Port Catheter. *Internal Medicine*. 2022;82:60-21.
18. Erinmez M, Zer Y, Manay AB. *Rhodotorula* fungemia in a patient with acute lymphoblastic leukemia. *Revista de Epidemiologia e Controle de Infecção*. 2022;12(1).
19. Guevara Robles M. Manual de procedimientos y técnicas de laboratorio para la identificación de los principales hongos oportunistas causantes de micosis humanas. In *Manual de procedimientos y técnicas de laboratorio para la identificación de los principales hongos oportunistas causantes de micosis humanas 2007* (pp. 100).
20. Pemán J, Cantón E, Calabuig E, et al. Actividad in vitro del voriconazol frente a levaduras y algas con los nuevos puntos de corte del patrón de resistencia. *Rev Esp Quimioter*. 2006;19(1):21-33.
21. Gomez-Lopez A. et al. In vitro antifungal susceptibility pattern and ergosterol content in clinical yeast strains. *Rev Iberoam Micol*. 2011;28(2):100-3.
22. Hoda Soliman, Ashraf Elsayed & Amira Dyaa. Antimicrobial activity of silver nanoparticles biosynthesised by *Rhodotorula* sp. strain ATL72, *Egyptian J Basic Appl Sci*. 5; (3):228-33
23. Cantón E, Viudes A, Pemán J. Infección sistémica nosocomial por levaduras. *Rev Iberoam Micol* 2001;18(1):51-55